We have read with great interest a study of Prof. Zhang regarding acute toxicity of
intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects.
1
In recent decades, infections caused by multiple drug-resistant (MDR)-Gram-negative
bacteria (GNB) have become a major public health threat worldwide and a challenge
to current antibiotic therapy.
2
MDR-GNB are associated with high mortality, and effective empirical therapy is vital
for patient survival.
3
,4
Patients with hematological diseases are at greater risk for MDR-GNB infection because
of myelosuppression, chemotherapy-induced gastrointestinal mucositis, extended hospitalization,
and regular exposure to broad-spectrum antibiotic therapy.
5
,6
Colonization has also been identified as a risk factor for infection.
7
.Keywords
Abbreviations:
MRD (Multiple drug-resistant), GNB (Gram-negative bacteria), CRO (Carbapenem-resistant organism), P. aeruginosa (Pseudomonas aeruginosa), K. pneumoniae (Klebsiella pneumoniae), S. maltophilia (Stenotrophomonas maltophilia), A. baumannii (Acinetobacter baumannii), E. coli (Escherichia coli)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of InfectionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects.J Infect. 2021; 82: 207-215
- Antimicrobial resistance—a threat to the world's sustainable development.Upsala J Med Sci. 2016; 121: 159-164
- Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibioticresistant gram-negative bacteria.Chest. 2008; 134: 281-287
- Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients.Intensiv Care Med. 2013; 39: 682-692
- The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies.Clin Infect Dis. 2014; 58: 1274-1283
- Bacterial infections in the stem cell transplant recipient and hematologic malignancy patient.Infect Dis Clin N Am. 2019; 33: 399
- Carbapenem-resistant enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non-carriers.J Hosp Infect. 2016; 94: 54-59
- Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society.Clin Infect Dis. 2016; 63: e61-111
- International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the european respiratory society (ERS), european society of intensive care medicine (ESICM), european society of clinical microbiology and infectious diseases (ESCMID) and asociación latinoamericana del Tórax (ALAT).Eur Respir J. 2017; 501700582
- Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.Crit Care. 2019; 23: 383
Article info
Publication history
Published online: January 23, 2023
Accepted:
January 17,
2023
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Published by Elsevier Ltd on behalf of The British Infection Association.
